Boston Therapeutics Appoints Zbigniew J. Witczak to its Scientific Advisory Board
News Jul 30, 2014
Boston Therapeutics, Inc. has appointed Zbigniew J. Witczak, Ph.D. to its Scientific Advisory Board (SAB). This brings the total number of Scientific Advisory Board members to six.
Dr. Witczak is professor and chair of the Department of Pharmaceutical Sciences at Wilkes University in Wilkes-Barre, Pennsylvania, and has taught Principles of Bioorganic and Medicinal Chemistry at the Nesbitt School of Pharmacy at Wilkes University for the past 14 years.
A member of the American Chemical Society, he is the recipient of numerous honors and awards, including Selected 2011 ACS Fellow of the American Chemical Society and Elected U.S. Representative to the International Carbohydrate Organization in 2006.
He is the author or coauthor of more than 75 research articles in the area of carbohydrate chemistry. He received Ph.D. and M.S. degrees in organic chemistry from Medical University in Lódz, Poland.
Dr. Witczak said, "The need for innovative treatments in diabetes has never been greater, in light of the increasing numbers of Americans with this disease. I believe Boston Therapeutics is doing valuable and innovative work in this area, and I am looking forward to helping guide the Company's development of its diabetes-related treatments."
Rom E. Eliaz, Ph.D., MBA, chair of the Boston Therapeutics' Scientific Advisory Board and member of the Company's Board of Directors, said, "The appointment of Dr. Witczak to the Board brings Boston Therapeutics an additional distinguished expert who will provide unique expertise to help guide the Company through its future endeavors."
David Platt, Chief Executive Officer of Boston Therapeutics, said, "We are extremely fortunate to have attracted Dr. Witczak to serve on our Scientific Advisory Board. We believe his decades of research experience will be a significant asset to us as we continue to seek the best path forward to helping those with diabetes."
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018